AGENIX LIMITED
爱健克斯有限公司
(ASX: AGX)

ABN 58 009 213 754
465 Auburn Road,
Hawthorn East,Vic, 3123
Australia
www.agenix.com

ASX MEDIA RELEASE 25 November 2010

Conversion of final tranche of Convertible Notes completed

Agenix Limited (ASX: AGX) (**Agenix**), announced that following the closure of the Rights Issue that Mr Tang Wen Sen has agreed to convert Notes totalling $200,000 into 40,000,000 Ordinary Shares in the Company at an issue price of $0.005 cents per share. Shareholder approval for the conversion was granted at the 2008 Annual General Meeting of the Company.

Executive Chairman stated "We are pleased that Mr Tang has agreed to convert the notes into ordinary shares. This further strengthens our financial position. The alternative would require redemption or extension to the repayment date due on 31 December 2010 in light of the proposed use of proceeds under the Rights Issue. Mr Tang has now converted, in total, Notes to the value of $400,000."

About Agenix Limited

Agenix is a publicly listed, Australian based international biotechnology company with a wholly owned subsidiary in China. The company has two core businesses:

- In **Innovative Biopharmaceuticals,** Agenix has 'in principal' rights to clinically develop a pipeline of innovative and proprietary Hepatitis B therapies for commercialisation in China. Through its wholly owned subsidiary, Agenix Biopharmaceutical (Shanghai), established in 2007, the company has established a collaboration with the Institute of Medicinal Biotechnology (**IMB**) of the Chinese Academy of Medical Sciences in Beijing to develop and commercialise AGX-1009, a next-generation, patented prodrug analog of an existing compound for the treatment of chronic HBV in China.

- In **Medical Diagnostics**, the company's lead indicator is a patented monoclonal antibody diagnostic called Thromboview® that, uniquely, detects live blood clots (DVT and PE) in the human body. ThromboView® has successfully completed two FDA Phase II human clinical trials in the United States. The company is positioning Thromboview® as an innovative diagnostic (a 'theranostic') to support the use of Novel Oral Anti-Coagulants and is seeking a development partner in China to commercialise the indicator.

Agenix has been listed on the Australian Securities Exchange (ASX: AGX) since 1987. Agenix is active in China, and seeking to establish commercial partnerships in the rest of the world. For additional information on Agenix Limited, please visit the company's website at http://www.agenix.com

Yours faithfully,

Nicholas Weston
Executive Chairman
Enclosures: Nil

CONTACT: Company Secretary Jeffrey Luckins:
+61 3 9822 8686 or email jluckins@agenix.com